202467-70-7

Basic information

• Product Name: (4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• Synonyms: (4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• CAS NO: 202467-70-7
• Molecular Weight: 789.777
• Mol File: 202467-70-7.mol

Chemical Properties

• Boiling Point: 1041.6±65.0 °C(Predicted)
• Density: 1.57±0.1 g/cm3(Predicted)
• CAS DataBase Reference: (4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(202467-70-7)
• EPA Substance Registry System: (4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate(202467-70-7)

Safety Data

• Hazardous Substances Data: 202467-70-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
(4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate is used as a compound in medicinal chemistry for its potential to be developed into a pharmaceutical agent. Its complex structure and functional groups may allow it to interact with biological targets in ways that could be beneficial for treating various diseases or conditions.
Used in Drug Development:
In the field of drug development, (4-nitrophenyl)methyl (4R,5S,6S)-3-[[(3S,5S)-5-[[(-carboxyphenyl)amino]carbonyl]-1-[[(4-nitrophenyl)methyoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate is utilized as a candidate molecule for the creation of new drugs. Its unique structural features may provide opportunities for the design of drugs with novel mechanisms of action, potentially leading to more effective treatments for a range of medical conditions.

Upstream product

• 202467-69-4 (2S,4S)-2-[[(3-carboxyphenyl)amino]carbonyl]-4-mercapto-1-(4-nitrobenzyl)pyrrolidine carboxylate 
• 93711-81-0 (4-nitrophenyl)methyl (4R,5R,6S)-3-[(diphenoxyphosphinyl)oxy]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 
• 90822-24-5 (γR,2R,3S)-α-diazo-3-[(1R)-1-hydroxyethyl]-γ-methyl-β,4-dioxo-2-azetidinebutanoic acid (4-nitrophenyl)methyl ester 
• 104873-15-6 4-nitrobenzyl (4R,5R,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3,7-dioxo-1-azabicyclo[3.2.0]-heptane-2-carboxylate 
• 189188-38-3 C₂₉H₂₇N₂O₁₀P 
• 189188-38-3 C₂₉H₂₇N₂O₁₀P 

Downstream Products

• 866186-68-7 6-[5-(3-carboxy-phenylcarbamoyl)-pyrrolidin-3-ylsulfanyl]-3,5-dimethyl-1-oxo-3,4,4a,5-tetrahydro-pyrrolo[1,2-c][1,3]oxazine-4,7-dicarboxylic acid 
• 153832-46-3 ertapenem 
• 153773-82-1 [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-3-[[-5-[[(3-carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monosodium 
• 1262305-54-3 C₄₄H₄₀N₆O₁₅S 

Relevant articles and documents

Synthesis method of ertapenem monosodium salt

The invention provides a synthesis method of an ertapenem monosodium salt. The method comprises the following steps: carrying out a reaction of a penem mother nuclear MAP and an ertapenem side chain to produce an intermediate product; and performing hydro

A double protection of the border he south cultivates the crystal and its preparation process

The present invention relates to the technical field of pharmaceutical intermediate synthesis, particularly to the technical field of a crystal form and a preparation process of an ertapenem intermediate, particularly to a crystal form and a preparation process of double-protection ertapenem, wherein the characteristic peaks of the double-protection group ertapenem crystal form exist when the 2[theta] angle is 5.7+/-0.2 DEG, 8.6+/-0.2 DEG, 12.8+/-0.2 DEG, 14.3+/-0.2 DEG, 15.8+/-0.2 DEG, 16.7+/-0.2 DEG, and 18.0+/-0.2 DEG.

PROCESS FOR PREPARATION OF ERTAPENEM AND SALTS THEREOF

The present invention relates to an improved process for the preparation of Ertapenem of formula (I) and its pharmaceutically acceptable salts, or hydrates, or solvates thereof. Formulae (I):

PROCESS TO PREPARE ERTAPENEM

The present invention relates to a novel process for the preparation of Ertapenem of formula (I) or salt thereof.

INTERMEDIATES OF CARBAPENEM, COMPOSITIONS CONTAINING THEM AND PREPARATION METHODS THEREOF

Intermediates of Ertapenem of formula 2a wherein Np represents (I) or (II), and P1 and P2 represent carboxyl protecting groups, and their preparation methods. Compound 2a prepared by the present methods in solid form is amorphous. Th

Improved process for the preparation of carbapenem using carbapenem intermediates and recovery of carbapenem

The present invention relates to preparing carbapenem intermediates that are useful to produce Ertapenem, Meropenem and Doripenem; and provides an effective process for recovering ertapenem compounds.

Preparation of Carbapenem Intermediate and Their Use

The present invention relates to preparing carbapenem intermediates that are useful to produce Ertapenem, Meropenem and Doripenem.

AN IMPROVED PROCESS FOR THE PREPARATION OF CARBAPENEM ANTIBIOTIC

The present invention provides a process for the preparation of the carbapenem antibiotic of formula (I) or its salt in amorphous form. Formula (I) wherein R represents hydrogen or COOM and M represents hydrogen or sodium.

AN IMPROVED PROCESS FOR THE PREPARATION OF CARBAPENEM ANTIBIOTIC

The present invention provides a process for the preparation of the carbapenem antibiotic of formula (I) or its salt in amorphous form. Formule(I) wherein R represents hydrogen or COOM and M represents hydrogen or sodium

Practical synthesis of the new carbapenem antibiotic ertapenem sodium

A practical synthesis for the large-scale production of the new carbapenem antibiotic, [4R,5S,6S]-3-[[(3S,5S)-5-[[(3-Carboxyphenyl)amino]carbonyl]-3- pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic aci